Lophius Biosciences is a biotech company focusing on the development of innovative T cell-based research tools and diagnostic systems for functional assessment of disease-reactive T cells.
Lophius Biosciences – early diagnosis and immunomonitoring
Lophius is focusing on the development of innovative T cell based research tools and diagnostic systems for the early diagnosis and immunomonitoring in the fields of transplantation, infectious and autoimmune diseases. Lophius flag ship product is T-Track CMV, a diagnostic system intended to determine the functionality of the cell-mediated immune response in cytomegalovirus (CMV) seropositive transplant patients who undergo an immunosuppressive therapy. Lophius Biosciences further expands its diagnostic T-Track product line by adding T-Track ImmunoScan and offering the T-activated ImmunoScan Cocktail for applications other than its IFNg ELISpot. Based on a proprietary and very specific cocktail of stimulants in combination with the Lophius’ T-activation technology, T-Track ImmunoScan and T-activated ImmunoScan Cocktail specifically target different cell types involved in both the adaptive and innate immune system. Both T-Track ImmunoScan and the T-activated ImmunoScan Cocktail are intended to be typically used in solid organ or bone marrow transplant recipients to measure the level of a change in immunosuppression with the ultimate goal to tailor immunosuppressive treatments to avoid both transplant rejection and infection with /reactivation of pathogens such as CMV, EBV, BKV, ADV or aspergillus. Other indications to assessing the patients’ functional immune status are rheumatic disorders, Inflammatory Bowel Disease, Cancer, HIV, and other immunosuppressive conditions. Thus, both products have the potential to significantly improve the standard of diagnosis and ultimately treatment of diseases associated with immunosuppression and emphasizes Lophius´ commitment to its goal of making truly personalized medicine broadly available in various indications.
Lophius Biosciences is a privately held biotech company headquartered in Regensburg (Germany). Management Team is composed by Robert Phelps, Ludwig Deml, Melanie Schmidmeier and Ralf Wagner. With its innovative products, Lophius Biosciences aims to significantly improve therapy control and personalized treatment of patients in the area of transplantation medicine, infectious and autoimmune diseases.
More about Lophius Biosciences : www.lophius.com